Details of Disease

General Information of Disease (ID: DIS0TXIR)

• Disease Name: Hepatitis E virus infection
• Synonyms: hepatitis type E; Hepatitis E virus hepatitis; Hepatitis E virus caused hepatitis
• Disease Class: 1E50: Acute viral hepatitis
• Definition: Acute inflammation of the liver in humans; caused by hepatitis E virus, a non-enveloped single-stranded rna virus. Similar to hepatitis A, its incubation period is 15-60 days and is enterically transmitted, usually by fecal-oral transmission.
• Disease Hierarchy:
  DISXXX35: Hepatitis
  DISVT5Q7: Viral hepatitis
  DISEM33Q: Infectious disease
  DIS0TXIR: Hepatitis E virus infection
• ICD Code: ICD-11: ICD-11: 1E50.4
• Disease Identifiers:
  MONDO ID: MONDO_0005788
  MESH ID: D016751
  UMLS CUI: C0085293
  MedGen ID: 88376
  SNOMED CT ID: 7.11E+12

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
HEV-239	DMGUC9T	Approved	Vaccine	[1]
GL-438	DM9QBKK	Phase 4	NA	[1]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APOA4	TTNC3WS	Disputed	Genetic Variation	[2]
DYRK3	TTV4EX0	Disputed	Biomarker	[3]
IFNL1	TTM624L	Disputed	Biomarker	[4]
SIRPA	TTBRJS9	Disputed	Biomarker	[5]
SLCO1A2	TTUGD21	Disputed	Biomarker	[6]
NR4A3	TTJQB49	Strong	Genetic Variation	[7]
TSG101	TTHU7JA	Strong	Biomarker	[8]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GPT	DER5HFI	Strong	Altered Expression	[9]

This Disease Is Related to 13 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
HFM1	OTHV3EFE	Limited	Genetic Variation	[10]
FARP2	OTNRQIMK	Disputed	Biomarker	[11]
GBF1	OTY1KEHY	Disputed	Biomarker	[12]
HOXC5	OTPQTLKZ	Disputed	Biomarker	[8]
IFIT1	OTXOQDSG	Disputed	Biomarker	[13]
IK	OTWSSXX0	Disputed	Biomarker	[3]
TMEM134	OTBX9H9D	Disputed	Biomarker	[14]
AHI1	OT8K2YWY	Strong	Biomarker	[15]
AMBP	OTLU8GU8	Strong	Biomarker	[16]
CCDC88A	OT3SSYYC	Strong	Biomarker	[17]
CHN1	OTM196M3	Strong	Genetic Variation	[7]
CPVL	OTOJL31C	Strong	Biomarker	[18]
NCKIPSD	OT24UORN	Strong	Biomarker	[15]

References

• [1] ClinicalTrials.gov (NCT02189603) Phase Clinical Trial of Recombinant Hepatitis E Vaccine ecolin . U.S. National Institutes of Health.
• [2] Evaluation of candidate genes associated with hepatitis A and E virus infection in Chinese Han population.Virol J. 2018 Mar 20;15(1):47. doi: 10.1186/s12985-018-0962-2.
• [3] Presence of Hepatitis E Virus in a RED Deer (Cervus elaphus) Population in Central Italy.Transbound Emerg Dis. 2017 Feb;64(1):137-143. doi: 10.1111/tbed.12353. Epub 2015 Apr 19.
• [4] Screening of novel drugs for inhibiting hepatitis E virus replication.J Virol Methods. 2019 Aug;270:1-11. doi: 10.1016/j.jviromet.2019.04.017. Epub 2019 Apr 17.
• [5] Hepatitis E virus infection activates signal regulator protein to down-regulate type I interferon.Immunol Res. 2016 Feb;64(1):115-22. doi: 10.1007/s12026-015-8729-y.
• [6] Chicken Organic Anion-Transporting Polypeptide 1A2, a Novel Avian Hepatitis E Virus (HEV) ORF2-Interacting Protein, Is Involved in Avian HEV Infection.J Virol. 2019 May 15;93(11):e02205-18. doi: 10.1128/JVI.02205-18. Print 2019 Jun 1.
• [7] Different susceptibility and pathogenesis of rabbit genotype 3 hepatitis E virus (HEV-3) and human HEV-3 (JRC-HE3) in SPF rabbits.Vet Microbiol. 2017 Aug;207:1-6. doi: 10.1016/j.vetmic.2017.05.019. Epub 2017 May 29.
• [8] Potent Inhibition of Hepatitis E Virus Release by a Cyclic Peptide Inhibitor of the Interaction between Viral Open Reading Frame 3 Protein and Host Tumor Susceptibility Gene 101.J Virol. 2018 Sep 26;92(20):e00684-18. doi: 10.1128/JVI.00684-18. Print 2018 Oct 15.
• [9] The association of elevated alanine aminotransferase levels with hepatitis E virus infections among blood donors in China.Transfusion. 2017 Feb;57(2):273-279. doi: 10.1111/trf.13991.
• [10] Genotyping of hepatitis E virus in clinical specimens by restriction endonuclease analysis.J Virol Methods. 1998 Jan;70(1):71-8. doi: 10.1016/s0166-0934(97)00172-9.
• [11] Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma.Antiviral Res. 2017 May;141:150-154. doi: 10.1016/j.antiviral.2017.02.011. Epub 2017 Feb 21.
• [12] Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication.Cell Microbiol. 2018 Jan;20(1):e12804. doi: 10.1111/cmi.12804. Epub 2017 Nov 17.
• [13] Hepatitis E virus polymerase binds to IFIT1 to protect the viral RNA from IFIT1-mediated translation inhibition.J Gen Virol. 2019 Mar;100(3):471-483. doi: 10.1099/jgv.0.001229. Epub 2019 Jan 31.
• [14] Systematic identification of hepatitis E virus ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-B pathway.Virus Res. 2017 Jan 15;228:102-108. doi: 10.1016/j.virusres.2016.11.027. Epub 2016 Nov 27.
• [15] First Crystal Structure of a Nonstructural Hepatitis E Viral Protein Identifies a Putative Novel Zinc-Binding Protein.J Virol. 2019 Jun 14;93(13):e00170-19. doi: 10.1128/JVI.00170-19. Print 2019 Jul 1.
• [16] The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor.J Virol. 2005 Sep;79(18):12081-7. doi: 10.1128/JVI.79.18.12081-12087.2005.
• [17] Molecular characterization of human enteric viruses in food, water samples, and surface swabs in Sicily.Int J Infect Dis. 2019 Mar;80:66-72. doi: 10.1016/j.ijid.2018.12.011. Epub 2019 Jan 9.
• [18] Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.Vaccine. 2008 Dec 2;26(51):6602-7. doi: 10.1016/j.vaccine.2008.09.035.